Navigation Links
Video: FDA Approves INVEGA(R) SUSTENNA(TM) for the Acute and Maintenance Treatment of Schizophrenia
Date:8/3/2009

TITUSVILLE, N.J., Aug. 3 /PRNewswire/ -- The U.S. Food and Drug Administration approved INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) extended-release injectable suspension for the acute and maintenance treatment of schizophrenia in adults on Friday, July 31, 2009. It is the first once-monthly, long-acting, injectable atypical antipsychotic approved in the U.S. for this use. Janssen((R)), Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc, will market INVEGA(R) SUSTENNA(TM) in the U.S.

To view the Multimedia News Release, go to: http://www.prnewswire.com/mnr/janssen/39116/

An estimated one percent of the world's population suffers from schizophrenia - a brain disorder that impairs a person's ability to think clearly, relate to others, and distinguish between reality and imagination. While there is no cure for schizophrenia, the symptoms and the risk of relapse (an exacerbation of symptoms) can be managed in most patients with appropriate treatment that includes continuous, long-term therapy with antipsychotic medications.(1)

Unfortunately, 80 percent of patients with schizophrenia experience at least one relapse within five years of diagnosis(2), and the risk for relapse in patients can substantially increase as a result of non-adherence.(2) Research shows that many patients treated with an oral atypical antipsychotic miss taking medication for about one-third of the year (110 days).(3) Therefore, it is critical for healthcare professionals to ensure that patients are following their treatment plans in order to help reduce the risk of relapse, because prognosis and outcome can progressively decline with each successive relapse.(4)

"Inconsistent compliance with medications is arguably one of the single greatest impediments to managing the symptoms of schizophrenia and d
'/>"/>

SOURCE Janssen, Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Video: New Dove(R) Body Washes with NutriumMoisture(TM) Restore Skins Natural Moisture
2. Video: Phase III Study Data With Vandetanib (Zactima(TM)) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) Presented at American Society of Clinical Oncology
3. Video: Data on More Than 15 Novartis Oncology Compounds at ASCO Highlight Progress Toward Targeted Therapies for Diverse Tumor Types
4. Video: UCB Launches Vimpat(R) in the U.S. for Add-On Treatment of Epilepsy in Adults
5. Video: Partnership Unites UCB with Consumer Product Innovator OXO(R)
6. Video: ev3 Inc. Announces First Patient Enrollments in DEFINITIVE LE Post-Market Study
7. Video: Afinitor(R) Approved in US as First Treatment for Patients With Advanced Kidney Cancer After Failure of Either Sunitinib or Sorafenib
8. Video: Provectus PV-10 Interim Phase 2 Safety and Efficacy Results are as Good as or Better than Phase 1 Results
9. Video: Zometa(R) Reduces Risk of Breast Cancer Recurrence in Premenopausal Women, Study in The New England Journal of Medicine Reports
10. Video: Femara(R) First Aromatase Inhibitor to Indicate Survival Benefit Versus Tamoxifen When Taken for Five Years After Breast Cancer Surgery
11. Video: Tasigna(R) Demonstrates Rapid Response as Initial Therapy in Life-Threatening Form of Leukemia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2012)... May 23, 2012 Medical Tactile, Inc. (MTI), ... Incorporated, today announced that they have developed a pre-commercial ... sensor technology for breast cancer screening.  ... Komen Foundation, 1.6 million women worldwide were diagnosed with ... the disease. Although early detection is the best means ...
(Date:5/23/2012)... Kraton Performance Polymers, Inc. (NYSE: "KRA"), ... or SBCs , and PolyOne Distribution, a ... and solutions, announce the execution of a distribution ... PolyOne product line. "Kraton Polymers ... IR products due to their deep knowledge about ...
(Date:5/23/2012)... 2012  Insmed Incorporated (Nasdaq CM: INSM), a biopharmaceutical ... for its U.S. phase 2 clinical trial, T ... G reater E fficacy T rial ... in patients with non-tuberculous mycobacterial (NTM) lung disease. ... to support current NTM treatment recommendations, and no new ...
Breaking Medicine Technology:Medical Tactile, Inc. Announces a 3G-Wireless System for Breast Cancer Screening 2Medical Tactile, Inc. Announces a 3G-Wireless System for Breast Cancer Screening 3Medical Tactile, Inc. Announces a 3G-Wireless System for Breast Cancer Screening 4Cariflex™ Polyisoprene Products by Kraton Performance Polymers Added to PolyOne Distribution Product Line 2Cariflex™ Polyisoprene Products by Kraton Performance Polymers Added to PolyOne Distribution Product Line 3Insmed Incorporated Begins Screening Patients For TARGET-NTM U.S. Clinical Trial Of ARIKACE® In Patients With Non-tuberculous Mycobacterial Lung Disease 2Insmed Incorporated Begins Screening Patients For TARGET-NTM U.S. Clinical Trial Of ARIKACE® In Patients With Non-tuberculous Mycobacterial Lung Disease 3Insmed Incorporated Begins Screening Patients For TARGET-NTM U.S. Clinical Trial Of ARIKACE® In Patients With Non-tuberculous Mycobacterial Lung Disease 4Insmed Incorporated Begins Screening Patients For TARGET-NTM U.S. Clinical Trial Of ARIKACE® In Patients With Non-tuberculous Mycobacterial Lung Disease 5Resource savvy communities generate healthy sustainable changes 15181 1Resource savvy communities generate healthy sustainable changes 15181 2Radiation Oncology Services of America Inc to Work With Washington University on Quality Assurance Initiative 10552 1Radiation Oncology Services of America Inc to Work With Washington University on Quality Assurance Initiative 10552 2U S Court of Appeals Upholds Validity of Lillys Evista Patents Through March of 2014 10547 1U S Court of Appeals Upholds Validity of Lillys Evista Patents Through March of 2014 10547 2
... Nektar,Therapeutics (Nasdaq: NKTR ) today ... study,for NKTR-118 (PEG-naloxol), an oral treatment being ... clinical manifestations of,opioid-induced bowel dysfunction (OBD). The ... safety and tolerability,of NKTR-118 in patients experiencing ...
... Data and Emerging Clinical Practice Experience Support ... HYLENEX Efficacy and ... Inc.,(Nasdaq: HALO ), a biopharmaceutical company developing and commercializing,products ... of the INFUSE-LR clinical trial results in the Journal,of Palliative ...
Other Medicine Technology:Nektar Commences Phase 2 Trial of NKTR-118 (oral PEG-naloxol) Evaluating Efficacy and Safety as Treatment for Opioid-Induced Bowel Dysfunction 2Nektar Commences Phase 2 Trial of NKTR-118 (oral PEG-naloxol) Evaluating Efficacy and Safety as Treatment for Opioid-Induced Bowel Dysfunction 3Nektar Commences Phase 2 Trial of NKTR-118 (oral PEG-naloxol) Evaluating Efficacy and Safety as Treatment for Opioid-Induced Bowel Dysfunction 4Nektar Commences Phase 2 Trial of NKTR-118 (oral PEG-naloxol) Evaluating Efficacy and Safety as Treatment for Opioid-Induced Bowel Dysfunction 5Halozyme Therapeutics Announces Peer-Reviewed Publications of the INFUSE-LR Clinical Trial Results and Clinical Practice Experience With Hylenex 2Halozyme Therapeutics Announces Peer-Reviewed Publications of the INFUSE-LR Clinical Trial Results and Clinical Practice Experience With Hylenex 3Halozyme Therapeutics Announces Peer-Reviewed Publications of the INFUSE-LR Clinical Trial Results and Clinical Practice Experience With Hylenex 4Halozyme Therapeutics Announces Peer-Reviewed Publications of the INFUSE-LR Clinical Trial Results and Clinical Practice Experience With Hylenex 5
(Date:5/23/2012)... proteins of the same kind, thereby triggering skeletal and ... researchers from the RUB Heart and Diabetes Center NRW ... in an interdisciplinary research project with colleagues from the ... the Journal of Biological Chemistry . , ... forms stabilizing filaments inside of the cells. Different mutations ...
(Date:5/23/2012)... FRANCISCO Prior treatment with inhaled corticosteroids in ... pneumonia (CAP) is associated with a lower incidence ... new study from researchers in Spain. , A ... (excess fluid that accumulates between the two pleural ... that arises as a result of a pneumonia, ...
(Date:5/22/2012)... Bend Research Inc., a leading independent ... expansion of its existing hot-melt extrusion (HME) ... Leistritz twin-screw mixer/extruder. , The 18mm ... 27mm Leistritz and 19mm Baker Perkins extruder ... high-shear wet-granulation capabilities. Many projects have been ...
(Date:5/22/2012)... The uproar that began last year when the U.S. ... longer offer regular prostate-cancer tests to healthy men continued ... report. Overall, they stuck to their guns, stating that ... cancer, the PSA test, causes more harm than good ... even dangerous, treatments. , But many people simply don,t ...
(Date:5/22/2012)... , , TUESDAY, May 22 (HealthDay News) -- Two preliminary ... both the detection and treatment of pancreatic cancer. ... said they have fashioned a vaccine that, in early ... attacking cancer cells. The team -- from Case ... Cancer Center at University Hospitals Case Medical Center in ...
Breaking Medicine News(10 mins):Health News:Aggregating instead of stabilizing: New insights into the mechanisms of heart disease 2Health News:Long-term ICS use reduces pleural effusion in patients with CAP 2Health News:Psychological Science explains uproar over prostate-cancer screenings 2Health News:Studies See Advances in Detecting, Treating Pancreatic Cancer 2Health News:Studies See Advances in Detecting, Treating Pancreatic Cancer 3Health News:Studies See Advances in Detecting, Treating Pancreatic Cancer 4
... 18 Women,s, health and,environmental groups today called on ... wake of product tests released last week by the,Campaign ... an,independent lab, 61 percent (20 samples) contained detectable levels ... lipsticks with the highest lead,content were made by L,Oreal ...
... Decisions Network,(MDN) announces Food and Drug Administration 510(k) ... The MDN-CGS software is used,by hospital nurses to ... administered to patients with elevated levels of blood,glucose, ... to energy for survival. More and more ...
... to Reduce Number Denied by President, a Few in ... 2,000,children will join the ranks of the uninsured, adding ... public health insurance,according to new data released today by ... new analysis, American Families Face Harsh Reality: 2,000 Children,Join ...
... Mass., Oct. 18 Yankee Candle Company,Inc., the ... home fragrance, is,taking action in the fight against ... Logo: http://www.newscom.com/cgi-bin/prnh/20071018/NYTH093LOGO-b ) Yankee Candle ... breast,cancer awareness and research. The company is donating ...
... returning U.S. veterans , , THURSDAY, Oct. 18 (HealthDay News) ... when deciding how best to treat post-traumatic stress disorder ... of the data concludes. , The Institute of Medicine ... Affairs, which noted that about 12.6 percent of personnel ...
... Haas (NYSE:,ROH) announced today that it has ... used as a bonding alternative for pressure,sensitive ... like,door panels, interior pillars, instrument panels and ... before seen or thought possible,in an aqueous ...
Other Medicine News:Health News:Health Groups Call on Cosmetic Giant L'Oreal to Remove Lead From Lipstick 2Health News:FDA Clears MDN-CGS(R) Intravenous Insulin Dosing Software 2Health News:Families Face Harsh Reality: 2,000 Children Join the Uninsured Each Day 2Health News:Yankee Candle Company Sheds Some Light In The Fight Against Breast Cancer 2Health News:Value of Most Post-Traumatic Stress Treatments 'Uncertain' 2Health News:Value of Most Post-Traumatic Stress Treatments 'Uncertain' 3Health News:Value of Most Post-Traumatic Stress Treatments 'Uncertain' 4Health News:New Water-Based Acrylic Pressure-Sensitive Adhesive Defeats Heat and Humidity Issue 2
The CapSureFix line of pacing leads combines the benefits of steroid-eluting technology with screw-in active fixation, to allow long-lasting, low-threshold delivery of pacing therapies....
... Physique leads are small profile endocardial permanent ... With a lead body size of only ... of 7 F, the Physique lead is ... today. Available in both straight and pre-formed ...
Used with permanent pacing leads....
...
Medicine Products: